Sugi Predict

Sugi Predict / Compounds / SCHEMBL705705

SCHEMBL705705

SCHEMBL705705

O=C(Nc1ccn(Cc2ccc(O)cc2C(F)(F)F)n1)c1c(F)cccc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STIM1 Q13586 2/20 1.00
▸ ORAI1 Q96D31 2/20 1.00
▸ ORAI3 Q9BRQ5 1/20 1.00
▸ SMN1; SMN2 Q16637 10/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ RAB9A P51151 5/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ LMNA P02545 7/20 0.45
▸ NPSR1 Q6W5P4 4/20 0.45
▸ HTT P42858 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ STAT3 P40763 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ GAA P10253 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29420774 1.00 STIM1 (1.00) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL757593 0.99 STIM1 (0.98) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL757594 0.99 STIM1 (0.98) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL757322 0.92 STIM1 (0.85) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL30096549 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL760584 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL30096575 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL758441 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL705056 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1
SCHEMBL30096572 0.89 STIM1 (0.80) STIM1ORAI1ORAI3SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116261468-A Methods and compositions for treating acute kidney injury 钙医学公司 2023-06-13 — — CN claimed
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME AVENUE CAPITAL MANAGEMENT II, L.P. 2023-04-20 — — US claimed
EP-4153179-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY Calcimedica, Inc. (US) 2023-03-29 — — EP claimed
CN-115835878-A Methods and compositions for treating acute lung injury and acute respiratory distress syndrome 钙医学公司 2023-03-21 — — CN claimed
EP-4121089-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME Calcimedica, Inc. (US) 2023-01-25 — — EP claimed
WO-2021236820-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY CALCIMEDICA, INC. (US) 2021-11-25 — — WO claimed
CN-113557020-A Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof 瑞真药业公司 2021-10-26 — — CN claimed
WO-2021189013-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME CALCIMEDICA, INC. (US) 2021-09-23 — — WO claimed
US-20180235958-A1 PANCREATITIS TREATMENT AVENUE CAPITAL MANAGEMENT II, L.P. 2018-08-23 — — US claimed
EP-3261641-A1 PANCREATITIS TREATMENT Calcimedica, Inc. (US) 2018-01-03 — — EP claimed
US-20170114060-A1 NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-04-27 — — US claimed
WO-2016138472-A1 PANCREATITIS TREATMENT CALCIMEDICA, INC. (US) 2016-09-01 — — WO claimed
WO-2015187827-A1 NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-12-10 — — WO claimed
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome CALCIMEDICA, INC. (US) 2026-02-10 — — US disclosed
EP-4275705-B1 PANCREATITIS TREATMENT CALCIMEDICA INC (US) 2025-05-14 — — EP disclosed
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS AVENUE CAPITAL MANAGEMENT II, L.P. 2025-04-17 — — US disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome ORAI1, MAVS, CASR STIM1 231/4885ORAI1 1/4885ORAI3 632/4885
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS IL1B, MAVS, MMP8 STIM1 852/4885ORAI1 92/4885ORAI3 1278/4885
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME MAVS, ATF1, IL1B STIM1 943/4885ORAI1 68/4885ORAI3 1408/4885
US-20170114060-A1 NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME ZC3HAV1, MAVS, EIF2AK2 STIM1 2753/4885ORAI1 3769/4885ORAI3 1449/4885
US-20180235958-A1 PANCREATITIS TREATMENT IAPP, PNLIP, VIP STIM1 249/4885ORAI1 40/4885ORAI3 373/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 STIM1 2564/4885ORAI1 3127/4885ORAI3 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.